Real-time Estimate
Cboe BZX
12:25:59 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
3.99
USD
|
-0.75%
|
|
+0.51%
|
-38.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
593.8
|
467.6
|
378.4
|
328.8
|
1,120
|
1,069
|
-
|
-
|
Enterprise Value (EV)
1 |
383.1
|
314.3
|
68.11
|
-53.95
|
879.8
|
361.9
|
445.1
|
404.4
|
P/E ratio
|
-4.58
x
|
-3.24
x
|
-2.63
x
|
-1.21
x
|
-5.37
x
|
-4.5
x
|
-7.62
x
|
-19.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
204
x
|
273
x
|
162
x
|
51.7
x
|
660
x
|
48.5
x
|
14.9
x
|
5.87
x
|
EV / Revenue
|
132
x
|
183
x
|
29.2
x
|
-8.48
x
|
518
x
|
16.4
x
|
6.21
x
|
2.22
x
|
EV / EBITDA
|
-2.79
x
|
-1.95
x
|
-0.44
x
|
0.35
x
|
-
|
-2.53
x
|
-2.6
x
|
-3.87
x
|
EV / FCF
|
-3.2
x
|
-2.37
x
|
-0.54
x
|
0.44
x
|
-5.62
x
|
-3.53
x
|
-6.07
x
|
291
x
|
FCF Yield
|
-31.3%
|
-42.1%
|
-186%
|
228%
|
-17.8%
|
-28.3%
|
-16.5%
|
0.34%
|
Price to Book
|
2.33
x
|
2.23
x
|
1.51
x
|
1.1
x
|
10
x
|
1.93
x
|
2.78
x
|
4.16
x
|
Nbr of stocks (in thousands)
|
44,982
|
52,299
|
72,919
|
173,059
|
173,937
|
265,926
|
-
|
-
|
Reference price
2 |
13.20
|
8.940
|
5.190
|
1.900
|
6.440
|
4.020
|
4.020
|
4.020
|
Announcement Date
|
3/3/20
|
3/4/21
|
3/10/22
|
3/7/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.908
|
1.715
|
2.33
|
6.36
|
1.698
|
22.04
|
71.64
|
182.2
|
EBITDA
1 |
-137.4
|
-160.8
|
-154.2
|
-154.3
|
-
|
-143.2
|
-171.1
|
-104.6
|
EBIT
1 |
-142
|
-166.4
|
-162.7
|
-161.7
|
-179.7
|
-207.6
|
-155
|
-75.48
|
Operating Margin
|
-4,881.77%
|
-9,704.37%
|
-6,981.55%
|
-2,542.23%
|
-10,583.1%
|
-941.96%
|
-216.31%
|
-41.43%
|
Earnings before Tax (EBT)
1 |
-139
|
-166.3
|
-166
|
-173.2
|
-208.4
|
-219.9
|
-143
|
-67.63
|
Net income
1 |
-123.8
|
-142.1
|
-142.1
|
-148.8
|
-208.4
|
-216.1
|
-132
|
-57.71
|
Net margin
|
-4,258.91%
|
-8,285.36%
|
-6,098.54%
|
-2,340.24%
|
-12,272.26%
|
-980.5%
|
-184.2%
|
-31.67%
|
EPS
2 |
-2.880
|
-2.760
|
-1.970
|
-1.570
|
-1.200
|
-0.8933
|
-0.5277
|
-0.2082
|
Free Cash Flow
1 |
-119.8
|
-132.4
|
-126.7
|
-123.1
|
-156.6
|
-102.5
|
-73.28
|
1.39
|
FCF margin
|
-4,120.53%
|
-7,722.39%
|
-5,438.54%
|
-1,936.31%
|
-9,221.02%
|
-464.93%
|
-102.29%
|
0.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/20
|
3/4/21
|
3/10/22
|
3/7/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.236
|
0.18
|
0.166
|
-
|
2.369
|
3.825
|
1.292
|
-
|
0.406
|
-
|
10.09
|
-
|
0.0667
|
1.752
|
17.64
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-40.36
|
-46.87
|
-41.62
|
-46.48
|
-43.49
|
-32.46
|
-43.1
|
-47.89
|
-47.82
|
-40.89
|
-38.76
|
-51
|
-54.05
|
-52.44
|
-40.29
|
Operating Margin
|
-17,099.58%
|
-26,038.89%
|
-25,071.08%
|
-
|
-1,835.96%
|
-848.71%
|
-3,336.22%
|
-
|
-11,779.31%
|
-
|
-384.07%
|
-
|
-81,072.69%
|
-2,993.84%
|
-228.41%
|
Earnings before Tax (EBT)
1 |
-39.38
|
-48.09
|
-42.69
|
-49.53
|
-48.92
|
-32.07
|
-43.78
|
-49.02
|
-50.79
|
-64.81
|
-52.7
|
-54.55
|
-57.14
|
-54.81
|
-40.29
|
Net income
1 |
-33.99
|
-41.67
|
-37.06
|
-42.06
|
-42.77
|
-26.95
|
-39.81
|
-45.55
|
-45.85
|
-77.17
|
-52.69
|
-51.62
|
-54.02
|
-51.92
|
-40.29
|
Net margin
|
-14,402.97%
|
-23,147.78%
|
-22,326.51%
|
-
|
-1,805.28%
|
-704.6%
|
-3,081.35%
|
-
|
-11,292.86%
|
-
|
-522.15%
|
-
|
-81,025.78%
|
-2,964.12%
|
-228.41%
|
EPS
2 |
-0.4700
|
-0.5100
|
-0.4100
|
-0.4600
|
-0.4700
|
-0.2300
|
-0.2300
|
-0.2600
|
-0.2600
|
-0.4500
|
-0.2400
|
-0.2167
|
-0.2200
|
-0.2233
|
-0.1933
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/10/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/7/23
|
5/4/23
|
8/3/23
|
11/2/23
|
3/14/24
|
5/17/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
211
|
153
|
310
|
383
|
240
|
707
|
624
|
665
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-120
|
-132
|
-127
|
-123
|
-157
|
-102
|
-73.3
|
1.39
|
ROE (net income / shareholders' equity)
|
-50.8%
|
-61.1%
|
-54.3%
|
-48.6%
|
-102%
|
-42.7%
|
-34.3%
|
-43.5%
|
ROA (Net income/ Total Assets)
|
-44.4%
|
-47.5%
|
-40.6%
|
-33.2%
|
-48.1%
|
-21.6%
|
-18.5%
|
-18.4%
|
Assets
1 |
278.9
|
298.9
|
349.9
|
447.9
|
432.8
|
999.7
|
711.8
|
313.9
|
Book Value Per Share
2 |
5.660
|
4.010
|
3.450
|
1.730
|
0.6400
|
2.080
|
1.440
|
0.9700
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-1.060
|
-0.1700
|
-0.1800
|
-0.2300
|
Capex
1 |
18.3
|
14.7
|
8.86
|
10.8
|
11
|
13.1
|
12.9
|
14
|
Capex / Sales
|
630.71%
|
856.03%
|
380.13%
|
170.46%
|
647%
|
59.42%
|
18.07%
|
7.68%
|
Announcement Date
|
3/3/20
|
3/4/21
|
3/10/22
|
3/7/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
4.02
USD Average target price
10.54
USD Spread / Average Target +162.30% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.66% | 1.07B | | +8.19% | 115B | | +13.03% | 107B | | -13.65% | 22.31B | | -3.99% | 21.6B | | -5.69% | 18.23B | | -39.93% | 17.62B | | +7.35% | 14.26B | | +33.48% | 12.37B | | -28.25% | 8.28B |
Bio Therapeutic Drugs
|